Regeneron Pharmaceuticals, Inc. (BMV:REGN)

Market Cap	1.24T
Revenue (ttm)	261.34B
Net Income (ttm)	83.97B
Shares Out	n/a
EPS (ttm)	762.93
PE Ratio	14.78
Forward PE	14.08
Dividend	51.49 (0.48%)
Ex-Dividend Date	Aug 18, 2025

Volume	10
Average Volume	175
Open	10,700
Previous Close	10,576
Day's Range	10,700 - 10,700
52-Week Range	9,420 - 18,704
Beta	n/a
RSI	66.13
Earnings Date	Oct 28, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: REGN

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD